Verona Pharma PLC is a clinical‐stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapies for respiratory diseases. Incorporated in 2005 and based in London, the company operates American Depositary Shares on the NASDAQ under the symbol VRNA. Verona Pharma’s primary focus is on inhaled and nebulized medicines designed to improve lung function and alleviate symptoms in patients suffering from chronic obstructive pulmonary disease (COPD), asthma and other respiratory conditions.
The company’s lead product candidate, ensifentrine (RPL554), is a first‐in‐class, dual inhibitor of phosphodiesterase 3 and 4 (PDE3/4) administered via inhalation or nebulization. In pivotal Phase 3 ENHANCE clinical trials, ensifentrine demonstrated statistically significant improvements in lung function, symptom scores and quality of life measures, supporting submissions for regulatory approval in both the United States and European Union. Verona Pharma is also exploring additional indications for ensifentrine, including cystic fibrosis and other forms of airway inflammation.
Verona Pharma maintains research and development facilities in the United Kingdom and the United States, leveraging contract manufacturing partners to scale production of its inhalation and nebulization formulations. The company conducts multi‐center clinical trials across North America, Europe and Asia, collaborating with leading respiratory specialists and academic institutions to ensure robust data generation and patient access. Verona Pharma’s integrated global infrastructure supports all stages of product development, from preclinical proof of concept through late‐stage clinical studies and regulatory interactions.
Since its founding, Verona Pharma has been led by an experienced management team and board of directors with deep expertise in respiratory medicine, drug development and regulatory strategy. Chief Executive Officer Nagraj Kashyap and Chief Financial Officer Mark Hornbrook bring decades of biopharmaceutical leadership to the organization, guiding the company through key milestones in clinical advancement and corporate growth. With a focus on innovative science and patient‐centric development, Verona Pharma aims to deliver new treatment options that address unmet needs in respiratory care.
AI Generated. May Contain Errors.
Free VRNA Stock Alerts